Study of Ravulizumab in Pediatric Participants With HSCT-TMA

  • STATUS
    Recruiting
  • End date
    Feb 29, 2024
  • participants needed
    40
  • sponsor
    Alexion Pharmaceuticals
Updated on 31 July 2021

Summary

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.

Details
Condition Thrombotic microangiopathy
Treatment Best supportive care, Ravulizumab
Clinical Study IdentifierNCT04557735
SponsorAlexion Pharmaceuticals
Last Modified on31 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

1 month of age up to < 18 years of age at the time of signing the informed consent
Received HSCT within the past 6 months
Diagnosis of TMA that persists despite initial management of any triggering condition
Body weight 5 kilograms
Female participants of childbearing potential and male participants with female partners of childbearing potential must use highly effective contraception starting at Screening and continuing until at least 8 months after the last dose of ravulizumab
Participants must be vaccinated against meningococcal infections if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. Participants must be re-vaccinated against Haemophilus influenzae type b and Streptococcus pneumoniae if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. All participants should be administered coverage with prophylactic antibiotics according to institutional post-transplant infection prophylaxis guidances, including coverage against Neisseria meningitidis for at least 2 weeks after meningococcal vaccination. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis coverage against Neisseria meningitidis the entire Treatment Period and for 8 months following the final dose of ravulizumab

Exclusion Criteria

Known familial or acquired 'a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13' deficiency (activity < 5%)
Known Shiga toxin-related hemolytic uremic syndrome
Positive direct Coombs test
Diagnosis or suspicion of disseminated intravascular coagulation
Known bone marrow/graft failure
Diagnosis of veno-occlusive disease
Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody titer)
Unresolved meningococcal disease
Presence or suspicion of sepsis (treated or untreated) within 7 days prior to Screening
Pregnancy or breastfeeding
Hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab
Previously or currently treated with a complement inhibitor
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note